Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Serina Therapeutics, Inc.

Filed: Apr 15, 2026HUNTSVILLE, ALCIK: 0001708599
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Serina Therapeutics appointed Dr. Srini Tenjarla as Chief Technology Officer, promoting him from Senior Vice President of CMC and Formulation, while also increasing CEO Steve Ledger's salary to $500,000. This leadership restructuring signals the company's focus on strengthening operational and strategic capabilities.

Key Takeaways

Dr. Srini Tenjarla promoted to Chief Technology Officer effective April 20, 2026, from his previous role as SVP of CMC and Formulation since July 2024

Dr. Tenjarla's new annual base salary is $425,000 following his promotion

2 more takeaways

Filing Overview

Form Type8-K
Filing DateApr 15, 2026
Item5.02
CategoryExecutive Change
CIK0001708599
Accession #ser-20260415
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
executive hireleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings